

# SOLUTION

Acorai has developed the first handheld, non-invasive intracardiac pressure monitor to **improve workflow efficiencies and patient outcomes**



**Strong IP position:** 3 granted patent families, 4 patent families pending large proprietary datasets

## UNIQUE & SUPERIOR TECHNOLOGY



- **Built on the patented SAVE Sensor System**

Combining **S**eismocardiography (**SCG**), **A**coustic (**PCG**), **V**isual (**PPG**), and **E**lectrocardiography (**ECG**) sensors

- Combined with one of the largest datasets of its kind

## ACCURATE, ABSOLUTE AND ACTIONABLE



- **Within minutes, providing direct estimates of**

Right atrial pressure (**RAP**), pulmonary pressure (**PAP**), pulmonary capillary wedge pressure (**PCWP**)

- Clinically preferred output for heart failure treatment

## IMPROVED TIME AND COST EFFICIENCY



- **Remove delays in treatment and enable proactive care**

Acorai allows healthcare professionals to **diagnose**, risk **stratify**, **treat**, and **discharge** plan with fewer **resources**

- Reducing readmissions and hospital costs resulting in **average direct hospital care savings of \$1M p.a.**

# ACORAI'S CLINICAL STUDY DEMONSTRATES **EQUIVALENCE** TO THE GOLD STANDARD


With a cohort of 300 patients, Acorai has met clinical requirements and demonstrated its accuracy vs. right heart catheterization

- ➔ **Superiority to standard of care tools** in identifying critically ill HF patients<sup>3,4</sup>
- ➔ **Similar performance to implantable devices** in estimating pulmonary artery pressure<sup>1,2</sup>
- ➔ **Higher efficiency & measurement repeatability** versus the standard of care

## ACORAI RESULTS SUMMARY

	Mean error vs. RHC	Correlation to Gold-Standard	Sensitivity (mPAP >25 mmHg) <sup>4</sup>	AUC (PCWP >22 mmHg) <sup>3</sup>
<b>Acorai</b>	<b>-0.1 mmHg</b>	<b>0.65 - 0.81</b>	<b>86%</b>	<b>0.87</b>
Standard of care	4.4 mmHg	0.41 - 0.65	48% - 85%	0.55 - 0.63

**ACORAI BLAND-ALTMAN PLOT**  
Diastolic Pulmonary Artery Pressure (dPAP)



**Acorai dPAP** error rate  
(2SD) vs. RHC:  
**12.2 mmHg**  
**Implantable device**  
**(CardioMEMS)**  
error rate vs. RHC (2SD)  
**11.8 mmHg**

Based on these results **“I am certain that most hospitals in the US would purchase this device even without reimbursement.”**

- Adam E. Berman (Cardiologist, Medical Director, Health Economist and Outcomes Researcher, Mississippi Baptist Health System)



# PRODUCT AND COMPANY KEY MILESTONES

To confirm equivalence to the gold standard in a global population to enable full market release by 2025

2023

- **Clinical:** 1000 patients enrolled at 10+ sites in EU and US
- **Product development:** Remote monitoring proof of concept data
- **Research partnership:** Pharma, diagnostics & device studies

2024

- **Clinical:** 300 patient approval pivotal study completed
- **Regulatory submissions:** US & EU approvals by Q4, 2024
- **Limited market release in US** and select EU markets

Today

2023 Q2

2024 Q1

2024 Q2

2025 Q1

Fully developed hardware & ML-architecture  
Pilot study - equivalence to gold standard

FDA Breakthrough Device designation  
Start global ML-generalization study

Finalized Machined Learning model  
Integration of ML into the final product

FDA De Novo submissions  
& CE-marking

**\$15m Series B raise**  
**Full commercial launch**



## STUDY SITES



Skåne University  
Hospital



Royal Brompton and  
Harefield hospitals



# A MULTI-DISCIPLINARY MANAGEMENT TEAM

Bringing deep technical, clinical, and commercial medical device experience to the table



**Filip Peters**  
CEO & Co-founder

8 years in finance, machine learning (ML) & hardware development. Leads hardware & ML development.



**+5 FTE engineers**



**Jakob Gelberg**  
CTO & Co-founder

8 years in software dev, marketing and B2B sales. Software development, product mgmt.



**+3 FTE engineers**



**Kasper Bourdette**  
COO & Co-founder

7 years in strategy & consulting. Responsible for operations & commercialization.



**Matthew Mace**  
Director of Sales

12+ years in MedTech business development. Ex-CardioMEMS at Abbott (clinical and sales). With \$20m+ in B2B Med Device launches.



**Helmine Verhoeven**  
Head of Clinical

20+ years experience leading clinical teams in the US & EU for Class I-III devices



**+1 clinical operations FTEs**



**Saray Ugidos Semán**  
Head of Quality & Reg.

10+ years within regulatory & quality affairs for medical devices (CE-marking & FDA)




**+2 regulatory FTEs**



**Niloufar Zarin**  
Head of Machine Learning

10+ years leading machine learning research teams in healthcare



**Dr. Chris Stokely**  
Cardiology physicist

R&D & IP - 20+ years experience of flow & pressure engineering from the oil & gas and space industries. Author of patents worth over \$30m

